Does Slow Viral Clearance and Viral Rebound During Infection Contribute to Long COVID?

The pathogenesis in how Long COVID developing remains a mystery and truly undefined as to why some people become afflicted by this condition and why others do not. However, investigators are gathering clues towards increasing evidence of how it takes hold. Annie Antar, MD, PhD, assistant professor of medicine, Johns Hopkins University School of Medicine […]

Top 5 Infectious Disease News Stories Week of March 1-8

Top FDA Approvals and Updates from February 2025 in Infectious Disease In February 2025, several key FDA approvals and updates in infectious disease included the approval of Bavarian Nordic’s Vimkunya vaccine for chikungunya, providing a single-dose option for those aged 12 and older. The FDA also approved GSK’s Penmenvy vaccine, offering protection against five meningococcal […]

IMUNON’s IMNN-101 Vaccine Shows Promising Results in Phase 1 Trial, Demonstrates Cross-Reactivity Against COVID Variants

IMUNON, Inc, a clinical-stage company focused on developing non-viral DNA-based immunotherapies, has announced promising results from its Phase 1 proof-of-concept clinical trial of IMNN-101, a DNA plasmid vaccine targeting COVID-19. The vaccine, developed using the company’s proprietary PlaCCine technology, demonstrated a sustained immune response with a 2- to 4-fold increase in neutralizing antibody (NAb) titers […]

Measles-Positive New Mexico Resident Dies, Cause of Death Still Unconfirmed

This is a developing story and will be updated as more information becomes available. Update March 7, 1:01pm ET: The Texas Department of State Health Services is reporting there have been 198 cases of measles confirmed since late January. Twenty-three of the patients have been hospitalized.1 This means since Texas authorities last reported the number […]

Insights from Investigator Evaluating Paxlovid’s Effectiveness in Vaccinated Older Adults

Katherine L Kahn, MD Image credits: UC Health Randomized clinical trials of nirmatrelvir-ritonavir (Paxlovid) have shown reduced COVID-19-related hospitalizations in unvaccinated individuals, but its effectiveness in vaccinated populations remains unclear. This question is particularly important for older adults, who are at higher risk for severe COVID-19 outcomes. In an exclusive interview with investigator Katherine L […]

Key Study Findings and Future Plans

Vaxart, Inc recently published complete data from its Phase 1b trial of its first-generation oral norovirus vaccine, demonstrating encouraging results in elderly adults. The study showed that the vaccine was capable of inducing strong antibody and T-cell responses in adults aged 55-80, a group known to experience weakened immune responses to traditional injectable vaccines. The […]

Cautionary Tale Associated in Trial With Rare Error in Cox Regression

The German company InflaRx has developed an investigational therapy, vilobelimab, which is being studied for SARS-CoV-2-induced acute respiratory distress syndrome (ARDS). Vilobelimab is a first-in-class monoclonal antihuman complement factor C5a antibody. In one of its trials, the FDA recommended that the company use a site stratification adjustment. “We had the FDA recommending us to do […]

Texas Outbreak Increases, Northeast Reports Cases, CDC Deployed to Help

On Tuesday, the Texas Department of State Health Services provided an update on the measles outbreak in there. Authorities reported there were 159 cases have been identified with 22 of the patients being hospitalized in western counties in the state. Gaines county has reported the highest number of cases with 107. There has been 1 […]

Invivyd’s Monoclonal Antibody Neutralizes Against Dominant COVID-19 Strain

Invivyd’s Chief Scientific Officer Robert Allen, PhDImage credit: Invivyd Today, Waltham, Mass.-based biopharmaceutical company,Invivyd, announced its monoclonal antibody, pemivibart (Pemgarda), continued to demonstrate neutralizing activity against the dominant strain of COVID-19, LP81. The variant did not generate any meaningful change to the neutralization activity of pemivibart or VYD2311, the company’s next generation COVID-19 monoclonal antibody […]